CytoMed Therapeutics (NASDAQ:GDTC) Limited chairman Peter Choo and chief operating officer Dr Wee Kiat Tan speak with Proactive following the company’s IPO on the Nasdaq in April 2023, which raised US$9,649,476. CytoMed was spun out from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. It’s a pre-clinical biopharmaceutical company focused on using its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers.
CytoMed creating novel cell-based immunotherapies for cancer treatment
